重组人干扰素联合阿德福韦酯治疗慢性乙型肝炎的疗效观察

摘要目的探讨重组干扰素联合阿德福韦酯治疗慢性乙型肝炎的临床疗效。方法将2011年12月－2012年12月72例慢性乙肝患者随机分成二组：对照组36例单纯采用重组人干扰素α－2b治疗；治疗组36例采用重组人干扰素α－2b＋阿德福韦酯治疗；比较二组临床疗效、乙肝病毒脱氧核糖核酸（HBVDNA）转阴率、乙肝病毒e抗原（HBeAg）转阴率、HBeAg血清转换率和患者肝功能指标水平的变化情况。结果治疗组的总有效率明显高于对照组（P〈0．05）；治疗组治疗后的HBVDNA转阴率、HBeAg转阴率、HBeAg血清转换率均显著高于对照组（P〈0．05）；治疗组患者治疗后的丙氨酸转氨酶（ALT）、冬氨酸转氨酶（AST），与对照组差异无统计学意义。结论重组人干扰素联合阿德福韦酯治疗慢性乙型肝炎，提高乙肝病毒标志物转阴率，改善肝功能水平。

THERAPEUTIC EFFECT OF RECOMBINANT HUMAN INTERFERON COMBINED WITH ADEFOVIR DIPIVOXIL IN THE TREATMENT OF CHRONIC HEPATITISB

Objective To evaluate the clinical efficacy of recombinant interferon in combination with adefovir dipivoxil in the treatment of chronic hepatitis B. Methods Totally 72 cases of chronic hepatitis B patients in author＇s hospital between December 2011 and December 2012 were randomly divided into two groups, 36 cases in each group. The control group was treated with only recombinant human interferon alpha -2b; while the treatment group was treated with recombinant human interferon alpha-2b and adefovir dipivoxil. The clinical efficacy two groups was compared on HBV- DNA negative rate, hepatitis Bvirus e antigen（HBeAg） negative rate, changes of HBeAg seroconversion rates and liver function indexes. Results The total effective rate in treatment group was significantly higher than the control group （P〈 0.05） ; After treatment, HBV-DNA negative conversion rate, HBeAg negative conversion rate, HBeAg seroconversion rates were significantly higher than the control groups （P〈0. 05） ; There was no significant difference between the control group and the treatment group on alanine aminotransferase （ALT）, aspartate transaminase （AST） after the treatment. Conclusion Recombinant human interferon and adefovir therapy in chronic hepatitis B can improve the hepatitis B virus marker negative rate and the level of liver function.